Routine health screenings may not reduce death risk, study finds—though early detection remains key.
Advertisement
Elevated [Lp(a)] is strongly associated with an increased risk of atherosclerotic cardiovascular disease.
This structural discovery is a step toward the development of next-generation therapies to modulate LDL.
Patient outreach with bulk ordering may result in higher lipid screening uptake than usual care.
A study found a comparable reduction in LDL-C with statins and bempedoic acid in patients with and without ASCVD.
Researchers have developed a machine learning model which can identify people who are likely to have elevated Lp(a).
Bempedoic acid treatment is similarly effective at lowering low-density lipoprotein cholesterol compared with statins.
Expert Interviews
Cardio Care Today delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.
Get the latest medical updates and insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.